© PR Newswire
07.01.2026
ABBV
LISTED
EURONEXT
AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
News Preview
NORTH CHICAGO, Ill., Jan. 7, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations websit...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2026
NVAX
LISTED
NASDAQ
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
GAITHERSBURG, Md., Jan. 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference.Conference Details:PresentationDate: Wednesday, January 14, 2026Time: 4:30 p.m. Pacific TimeLocation: San Francisco, CAA...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2026
CNC
LISTED
NYSE
Cityblock Health and Meridian Health Plan of Illinois Announce Partnership to Serve 10,000 Medicaid Members
News Preview
Innovative value-based care arrangement specifically targets complex challenges facing Medicaid beneficiaries in 17 Illinois countiesBROOKLYN, N.Y. and CHICAGO, Jan. 7, 2026 /PRNewswire/ -- Cityblock Health and Meridian Health Plan of Illinois, Inc. ("Meridian") today announced a partnership to bring comprehensive, community-based care to 10,000 M...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
07.01.2026
GMAB
LISTED
CPH
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
News Preview
Media ReleaseCOPENHAGEN, Denmark; January 07, 2026...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
07.01.2026
RPID
LISTED
NASDAQ
Rapid Micro Biosystems to Present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
LEXINGTON, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at th...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
JNJ
LISTED
NYSE
Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration
News Preview
Johnson & Johnson today announced that the company has submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in ge...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
EXEL
LISTED
NASDAQ
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
News Preview
Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 pivotal trial will evaluate zanzalintinib, Exelixis’ novel oral kinase inhibitor, with and without an immune checkpoint in...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
FBLG
LISTED
NASDAQ
FibroBiologics CEO Issues Letter to Shareholders
News Preview
HOUSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today issued the following lette...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 12:00 p.m. PT (3:00 p.m. ET) in San Francisco....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
IRON
LISTED
NASDAQ
Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., President and Chief Executive Of...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease characterized by triglyceride levels that can be 1...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
ICU
LISTED
NASDAQ
SeaStar Medical Announces 2026 Milestones
News Preview
Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
07.01.2026
ICCC
LISTED
NASDAQ
ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
News Preview
Conference Call Scheduled for Friday, January 9, 2026 at 9:00 AM ET Conference Call Scheduled for Friday, January 9, 2026 at 9:00 AM ET...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
CDNA
LISTED
NASDAQ
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a strategic collaboration with 10x Genomics (Nasdaq: TXG), a leader in singl...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2026
VEEV
LISTED
NYSE
Novo Nordisk International Operations Commits to Veeva Vault CRM
News Preview
Chooses industry leading Vault CRM to empower commercial teams with next-generation CRM capabilities and agentic AIPLEASANTON, Calif., Jan. 7, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Novo Nordisk's International Operations business unit has committed to use Veeva Vault CRM....
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2026
VEEV
LISTED
NYSE
Novo Nordisk International Operations Commits to Veeva Vault CRM
News Preview
Chooses industry leading Vault CRM to empower commercial teams with next-generation CRM capabilities and agentic AIPLEASANTON, Calif., Jan. 7, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Novo Nordisk's International Operations business unit has committed to use Veeva Vault CRM.
"We are honored to expand our partnership wit...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2026
SCNI
LISTED
XETRA
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
News Preview
JERUSALEM, Jan. 7, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO business unit, today announced that its Chief Executive Officer, Amir Reichman, will co-lead a roundtabl...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2026
GNPX
LISTED
NASDAQ
Genprex Provides Clinical Update on Diabetes Gene Therapy Program
News Preview
Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and StudiesAUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced a...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2026
BHVN
LISTED
NYSE
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
News Preview
NEW HAVEN, Conn., Jan. 7, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Monday, January 12, 2026, at 8:15 a.m. PST (11:15 a.m. EST)....
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2026
VKTX
LISTED
NASDAQ
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
News Preview
Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing ExpertiseSAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appo...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
TARA
LISTED
NASDAQ
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 pm PT in San Fr...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
FDMT
LISTED
NASDAQ
4DMT Provides Company Update and Anticipated Development Milestones for 2026
News Preview
EMERYVILLE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today provided a corporate update and o...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
SABS
LISTED
NASDAQ
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
News Preview
David Zaccardelli, Pharm.D. joins Board as Chair...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
VRCA
LISTED
NASDAQ
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
News Preview
– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity–...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
NWRN
LISTED
SIX
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
News Preview
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, is pleased to note that its partner EA Pharma Co., Ltd. (EAP), has announced today the initiation of its Phase III clinical trial with e...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
ACET
LISTED
NASDAQ
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and highlighted upcoming milestones for 2026.
“Heading into 2026, we are proud of the strong execution across our pipeline. Since reporting...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
MRK
LISTED
NYSE
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluating calderasib (MK-1084), an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
MRK
LISTED
NYSE
Merck to Complete Acquisition of Cidara Therapeutics
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”).
“The acquisition of Cidara strengthens and complements our expanding respiratory...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
PVLA
LISTED
NASDAQ
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
News Preview
Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA®, povorcitinib, ILUMYA®, ODOMZO®, REMICADE®, and STELARA®...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
VERA
LISTED
NASDAQ
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
News Preview
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
DYN
LISTED
NASDAQ
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morga...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
TGTX
LISTED
NASDAQ
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Presentation scheduled for Tuesday, January 13, 2026, at 1:30 PM PST Presentation scheduled for Tuesday, January 13, 2026, at 1:30 PM PST...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
SHC
LISTED
NASDAQ
Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
NTLA
LISTED
NASDAQ
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14,...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
SHL
LISTED
XETR
Social Media Influence in the Exam Room: National Survey About Medical Testing Reveals Changing Patient Expectations
News Preview
U.S.-based patients’ expectations for testing are changing, potentially at the expense of evidence-based medicine. Patients, feeling empowered by social media, want greater control over test ordering decisions, and some even dismiss doctors’ expertise, mirroring growing mistrust in authority. U.S.-based patients’ expectations for testing are changi...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
MRK
LISTED
NYSE
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Feb. 3. During the call, company executives will provide an overview of Merck’s performance for the quarter.
Investors, j...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
CMPS
LISTED
NASDAQ
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD
News Preview
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. C...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
LQDA
LISTED
NASDAQ
Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 beginning at approximately 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time) at the Westin St. Franci...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
RZLT
LISTED
NASDAQ
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
News Preview
Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
RAPP
LISTED
NASDAQ
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
News Preview
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter of 2026 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
GANX
LISTED
NASDAQ
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
News Preview
BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced its attendance at conferences during the week of the 44th Annual J.P. Morgan...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
GLUE
LISTED
NASDAQ
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
News Preview
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
BTAI
LISTED
NASDAQ
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
News Preview
Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
BBOT
LISTED
NASDAQ
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs
News Preview
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced positive preliminary safety and antitumor data across its three orally bioavailable, differentiated small molecule RAS and PI3...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
SNDX
LISTED
NASDAQ
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
News Preview
- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations -...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
EYPT
LISTED
NASDAQ
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
News Preview
– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –...
Themefolio
Profiler
Peergroup
© Newsfile
07.01.2026
HBFG
LISTED
CSE
Happy Belly Food Group's Multi-Unit Franchisee for Heal Wellness QSR in Alberta Secures 11th Real-Estate Location
News Preview
Toronto, Ontario--(Newsfile Corp. - January 7, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands, is pleased to announce that its multi-unit franchisee for Heal Wellness ("Heal") QSR in Alberta secures its 11th real estate location. This milestone fu...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
RDNT
LISTED
NASDAQ
RadNet Expands to Southwest Florida with Acquisition of Radiology Regional
News Preview
RadNet acquires Radiology Regional, adding 13 imaging centers in Southwest Florida....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2026
RDNT
LISTED
NASDAQ
RadNet Names Four Leaders to Expanded Executive Roles
News Preview
RadNet announces executive leadership transitions to support the Company’s continued growth....
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.01.2026
TRNR
LISTED
NASDAQ
TRNR Provides Shareholder Update on Sportstech Process & Operating Strategy
News Preview
AUSTIN, TEXAS / ACCESS Newswire / January 7, 2026 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or the "Company"), maker of innovative specialty fitness equipment under the Wattbike, CLMBR and FORME brands, today announced that it has published a shareholder letter updating investors with respect to the Sportstech loan and a...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.01.2026
MDCE
LISTED
OTC
Medical Care Technologies' Infinite Auctions to Offer Original Art by Iconic Artist Rob Prior Signed by Stan Lee, Chris Evans, Al Pacino & More
News Preview
MESA, ARIZONA / ACCESS Newswire / January 7, 2026 / Medical Care Technologies Inc. (OTC Pink:MDCE) is excited to announce that its subsidiary, Infinite Auctions, will host "The Legends Art Auction," an exclusive event showcasing a remarkable collection of original art pieces by renowned artist Rob Prior and others. This highly anticipated...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.01.2026
REVB
LISTED
NASDAQ
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development
News Preview
SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced the start of GMP manufacturing of GEMINI and placebo. This manufacturing run will provide the Company...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.01.2026
AIMD
LISTED
NASDAQ
Ainos Announces Distribution Partnership with Trusval Technology to Expand AI Nose into Semiconductor Front-End Manufacturing
News Preview
Partnership Supports Ainos' 2026 Strategic Focus on Advancing AI Nose Upstream and Accelerating Scent Data Accumulation in Advanced Wafer Fabs HOUSTON, TX / ACCESS Newswire / January 7, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a SmellTech platform company digitizing scent as a native data language for artificial intelligence, today announced...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
45680
LISTED
XJPX
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe
News Preview
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML).
Under the terms of...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2026
IONS
LISTED
NASDAQ
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the safety and efficacy of bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). The studies included over 1,800 patients from 29 coun...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.01.2026
OVAT
LISTED
CSE
Ovation Science Secures New Canadian Patent; Strengthening IP Position and Expanding Commercial Opportunities for Topical Cannabis Products
News Preview
Canadian Patent Enhances Market Exclusivity and Licensing PotentialExpands Global Intellectual Property Portfolio Supporting Long-Term Revenue Growth VANCOUVER, BC / ACCESS Newswire / January 7, 2026 / Ovation Science Inc. (CSE:OVAT)(OTC PINK:OVATF) ("Ovation" or the "Company"), a research and development company focused on the...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.01.2026
ASBP
LISTED
NASDAQ
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
News Preview
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial ESTERO, FL / ACCESS Newswire / January 7, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug de...
Themefolio
Profiler
Peergroup
© ActuNews
07.01.2026
ALTHX
LISTED
EURONEXT
THERANEXUS : THX Pharma Announces the Appointment of Julien Veys as Deputy Chief Executive Officer
News Preview
Lyon, France – January 7, 2026, 8:00 a.m. CET – The Board of Directors of THX Pharma (Theranexus), a pharmaceutical company specializing in rare neurological diseases, today announces the appointment of Julien Veys as Deputy Chief Executive Officer. This appointment is part of the continued development of THX Pharma and the implementati...
Themefolio
Profiler
Peergroup
© ActuNews
07.01.2026
ALTHX
LISTED
EURONEXT
THERANEXUS : THX Pharma annonce la nomination de Julien Veys au poste de Directeur général adjoint
News Preview
Lyon, France – 7 janvier 2026, 8h CET – Le Conseil d'administration de THX Pharma (Theranexus), société pharmaceutique spécialisée dans les maladies neurologiques rares, annonce aujourd'hui la nomination de Julien Veys au poste de Directeur général adjoint. Cette nomination s'inscrit...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.01.2026
OCEL
LISTED
OTC
Cytora Therapeutics, Made Scientific, and Zeo ScientifiX Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States
News Preview
Three-Way Collaboration to Bring Innovative Oral Mucosal Stem Cell Therapy with U.S. GMP Manufacturing and Commercialization Infrastructure to Patients Seeking Treatment for Non-healing Diabetic Foot Ulcers and Other Indications PRINCETON, NJ, DAVIE, FL, AND TEL AVIV, ISRAEL / ACCESS Newswire / January 7, 2026 / Cytora Therapeutics Ltd. (Cytora), a...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
